Question Everything. See who's reporting it.

Nucelion, VeGen Bio Partner for CAR-T Therapy

Source: The Hindu

The story in brief

Bharat Biotech's Nucelion Therapeutics has partnered with Hyderabad-based VeGen Bio to manufacture CAR-T therapy VL-2511 for multiple myeloma. The companies plan to advance the treatment to Phase 1/2 clinical trials in India and aim for commercialisation by 2028, pending regulatory approvals. The agreement focuses on manufacturing, not marketing or distribution.

3 outletsSee what the other 2 outlets said

NEWXFree on Android and iPhone. Open in NEWX